Classical ALK G1202R resistance mutation was identified in a lung adenocarcinoma patient with rare LOC388942-ALK fusion after sequential treatment with ALK-TKIs and anlotinib: a case report

BACKGROUND: Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) is a heterogeneous disease. To date, more than ninety ALK fusions in lung cancer have been found. Here, we report for the first time a rare LOC388942-ALK fusion in NSCLC was sensitive to crizotinib but resistant...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Xiaoqian, Liu, Yanyang, Liang, Zuoyu, Wang, Weiya, Qin, Tian, Liu, Stephen V., Um, Sang-Won, Luo, Feng, Liu, Jiewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
iMDT Corner
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708479/
https://www.ncbi.nlm.nih.gov/pubmed/36467355
http://dx.doi.org/10.21037/atm-22-5194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708479/
https://www.ncbi.nlm.nih.gov/pubmed/36467355
http://dx.doi.org/10.21037/atm-22-5194

Ejemplares similares